Topics covered: Therapeutic Cardiovascular Plays, Small- & Mid-Cap M&A Rally, Managing Inherent Volatility, Investable Trend In Antibody Technology, Impact Of Health Care Reform, Financial & Regulatory Risks To Drug Development, FDA Approval Process, Easing Capital Markets, Clinical, Basket Investment Approach
Companies covered: TCF Financial Corporation (NYSE:TCF), Royal Bank Of Canada (NYSE:RY), KeyCorp (NYSE:KEY), J P Morgan Chase & Co (NYSE:JPM), Fifth Third Bancorp (NASDAQ:FITB), First Horizon National Corporation (NYSE:FHN), Capital One Financial Corporation (NYSE:COF), Comerica Incorporated (NYSE:CMA), Citigroup Inc. (NYSE:C), Brunswick Corporation (NYSE:BC), Celgene Corporation (NASDAQ:CELG), Biogen Inc. (NASDAQ:BIIB), Seattle Genetics, Inc. (NASDAQ:SGEN), Pharmacyclics, Inc. (NASDAQ:PCYC), OSI Pharmaceuticals Inc., ImmunoGen, Inc. (NASDAQ:IMGN), Gilead Sciences, Inc. (NASDAQ:GILD), Facet Biotech Corporation, Celera Corporation, Cubist Pharmaceuticals Inc., Systemax Inc. (NYSE:SYX), Appalachian Bancshares Inc., Corcept Therapeutics Incorporated (NASDAQ:CORT), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), NBTY, Inc., AEterna Zentaris Inc. (NASDAQ:AEZS)
